Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update

키워드

참고문헌 (371)

1. Theodorides VJ, "Anthelmintic activity of albendazole against liver flukes, tapeworms, lung and intestinal roundworms", Experientia, 32, pp.702~703 (1976)[DOI]
2. Pene P, "Albendazole: a new broad spectrum anthelmintic. Double-blind multicenter clinical trial.", Am J Trop Med Hyg, 31, pp.263~266 (1982)[DOI]
3. Dayan AD, "Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics", Acta Trop, 86, pp.141~159 (2003)[DOI]
4. Brugmans JP, "Mebendazole in enterobiasis. Radiochemical and pilot clinical study in 1,278 subjects", JAMA, 217, pp.313~316 (1971)[DOI]
5. Pawluk SA, "A review of pharmacokinetic drug-drug interactions with the anthelmintic medications albendazole and mebendazole", Clin Pharmacokinet, 54, pp.371~383 (2015)[DOI]
6. Edwards G, "Clinical pharmacokinetics of anthelmintic drugs", Clin Pharmacokinet, 15, pp.67~93 (1988)[DOI]
7. Kern P, "Echinococcus granulosus infection: clinical presentation, medical treatment and outcome", Langenbecks Arch Surg, 388, pp.413~420 (2003)[DOI]
8. Chai JY, "Chemotherapy of intestinal nematode infections", J Korean Soc Chemother, 3, pp.119~129 (1985)
9. 채종일, "선충류 감염에 대한 구충제 사용의 최근 진전", Infection and Chemotherapy, 43(1), pp.26~35 (2011), 대한감염학회
10. Keiser J, "The drugs we have and the drugs we need against major helminth infections", Adv Parasitol, 73, pp.197~230 (2010)[DOI]
11. 홍성태, "Albendazole and Praziquantel: Review and Safety Monitoring in Korea", Infection and Chemotherapy, 50(1), pp.1~10 (2018), 대한감염학회
12. Jamet D, "Systemic microsporidiosis and toxoplasmosis in a patient with T lymphocytic leukemia", Med Mal Infect, 39, pp.406~408 (2009)[DOI]
13. Rim HJ, "Anthelmintic effects of albendazole (Zentel®) against helminthic infections", Korean J Rural Med, 9, pp.67~73 (1984)
14. Pungpark S, "Albendazole in the treatment of opisthorchiasis and concomitant intestinal helminthic infections", Southeast Asian J Trop Med Public Health, 15, pp.44~50 (1984)
15. Keiser J, "Chemotherapy for major food-borne trematodes : a review", Expert Opin Pharmacother, 5, pp.1711~1726 (2004)[DOI]
16. Fan PC, "Determination of the minimum effective dosages of praziquantel, albendazole, and mebendazole against Clonorchis sinensis infection in rats", Kaohsiung J Med Sci, 21, pp.448~451 (2005)[DOI]
17. han W, "Have we forgotten the threat posed by fascioliasis? A potential threat to public health", Iran J Public Health, 49, pp.814~815 (2020)
18. Xu LL, "Efficacy and safety of praziquantel, tribendimidine and mebendazole in patients with co-infection of Clonorchis sinensis and other helminths", PLoS Negl Trop Dis, 8, pp.e3046~ (2014)[DOI]
19. Jaroonvesama N, "Treatment of Opisthorchis viverrini with mebendazole", Southeast Asian J Trop Med Public Health, 12, pp.595~597 (1981)
20. Dugernier T, "Human fascioliasis : cure by mebendazole? A case report", Gastroenterol Clin Biol, 10, pp.513~516 (1986)
21. Rim HJ, "Anthelmintic effects of albendazole against Taenia saginata and Taenia solium infections", J Korean Soc Chemother, 7, pp.29~39 (1989)
22. Takayanagui OM, "Medical management of neurocysticercosis", Expert Opin Pharmacother, 12, pp.2845~2856 (2011)[DOI]
23. Steinmann P, "Efficacy of single-dose and triple-dose albendazole and mebendazole against soil-transmitted helminths and Taenia spp.: a randomized controlled trial", PLoS One, 6, pp.e25003~ (2011)[DOI]
24. Tamarozzi F, "Acceptance of standardized ultrasound classification, use of albendazole, and long-term follow-up in clinical management of cystic echinococcosis: a systematic review", Curr Opin Infect Dis, 2, pp.425~431 (2014)[DOI]
25. Qavi A, "Disseminated cysticercosis:clinical spectrum, Toll-like receptor-4 gene polymorphisms and role of albendazole", Medicine, 9, pp.e4882~ (2016)[DOI]
26. Molina JM, "Disseminated microsporidiosis due to Septata intestinalis in patients with AIDS: clinical features and response to albendazole therapy", J Infect Dis, 171, pp.245~249 (1995)[DOI]
27. Sak B, "Encephalitozoon cuniculi genotype III evinces a resistance to albendazole treatment in both immunodeficient and immunocompetent mice.", Antimicrob Agents Chemother, 64, pp.e00058~e00020 (2020)[DOI]
28. Darlan DM, "The comparison of efficacy and side effect between albendazole and metronidazole in the management of giardiasis: a systematic review and meta-analysis", EuroMeditter Biomed J, 15, pp.191~196 (2020)[DOI]
29. Palos I, "Esters of quinolone-7-carboxylate-1,4-di-N-oxide as Trichomonas vaginalis triosephosphate isomerase inhibitors", Acta Pharm, 71, pp.485~495 (2021)[DOI]
30. Sears SD, "In vitro susceptibility of Trichomonas vagina-lis to 50 antimicrobial agents", Antimicrobial Agents Chemother, 32, pp.144~146 (1988)[DOI]
31. Cedillo-Rivera R, "In-vitro susceptibility of Giardia lamblia to albendazole, mebendazole and other chemotherapeutic agents", J Med Microbiol, 37, pp.221~224 (1992)[DOI]
32. Patziarka P, "Repurposing drugs in oncology(ReDO)-mebendazole as an anti-cancer agent", Ecancermedicalscience, 8, pp.443~ (2014)[DOI]
33. Castro LSEPW, "Albendazole as a promising molecule for tumor control", Radix Biol, 10, pp.90~99 (2016)[DOI]
34. Guerini AE, "Mebendazole as a candidate for drug repurposing in oncology : an extensive review of current literature", Cancers, 11, pp.1284~ (2019)[DOI]
35. 손덕수, "The Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing Drugs", Immune Network, 20(4), pp.e29~ (2020), 대한면역학회[DOI]
36. Braithwaite PA, "Hydatid disease:the alveolar variety in Australia. A case report with comment on the toxicity of mebendazole", Aust N Z J Surg, 55, pp.519~523 (1985)[DOI]
37. Morris DL, "Pilot study of albendazole in patients with advanced malignancy", Oncology, 61, pp.42~46 (2001)[DOI]
38. Pourgholami MH, "In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole", Cancer Lett, 165, pp.43~49 (2001)[DOI]
39. 문상이, "알벤다졸의 예방적 투약에 의한 약물 유발 간 손상 1예", 대한소화기학회지, 73(6), pp.360~364 (2019), 대한소화기학회[DOI]
40. Krücken J, "Reduced efficacy of albendazole against Ascaris lumbricoides in Rwandan schoolchildren", Int J Parasitol Drugs Drug Resist, 7, pp.262~271 (2017)[DOI]
41. Rashwan N, "Isothermal diagnostic assays for monitoring single nucleotide polymorphisms in Necator americanus associated with benzimidazole drug resistance", PLoS Negl Trop Dis, 10, pp.e0005113~ (2016)[DOI]
42. Moser W, "Drug combinations against soiltransmitted helminth infections", Adv Parasitol, 103, pp.91~115 (2019)[DOI]
43. Moser W, "Efficacy of recommended drugs against soil transmitted helminths: systematic review and network meta-analysis", BMJ, 358, pp.j4307~ (2017)[DOI]
44. Soukhathammavong PA, "Low efficacy of single-dose albendazole and mebendazole against hookworm and effect on concomitant helminth infection in Lao PDR", PLoS Negl Trop Dis, 6, pp.e1417~ (2012)[DOI]
45. World Health Organization, "WHO Model Prescribing Information: Drugs Used in Parasitic Diseases", pp.1~146 (1995), World Health Organization
46. 채종일, "Effect of Mass Drug Administration with a Single Dose of Albendazole on Ascaris lumbricoides and Trichuris trichiura Infection among Schoolchildren in Yangon Region, Myanmar", The Korean Journal of Parasitology, 58(2), pp.195~200 (2020), 대한기생충학ㆍ열대의학회[DOI]
47. Chaia G, "Therapeutic action of mebendazole (R 17,635) against human helminthiasis", Fôlha Med, 63, pp.843~852 (1971)
48. havarría AP, "Mebendazole, an effective broad-spectrum anthelmintic", Am J Trop Med Hyg, 22, pp.592~595 (1973)[DOI]
49. Seo BS, "Reduced single dose of mebendazole in treatment of Ascaris lumbricoides infection", Korean J Parasitol, 16, pp.21~25 (1978)[DOI]
50. Abadi K, "Single dose mebendazole therapy for soil-transmitted nematodes", Am J Trop Med Hyg, 34, pp.129~133 (1985)
51. Pene P, "Le Zentel® dans traitement des helminthiases intestinales en Afrique de l’Ouest", Méd Afr Noire, 29, pp.43~48 (1982)
52. Soula G, "Le Zentel® dans le traitement des nématodoses intestinales en République Centrafricaine", Méd Afr Noire, 29, pp.29~32 (1982)
53. Horton J, "Albendazole: a review of anthelmintic efficacy and safety in humans", Parasitology, 121(suppl), pp.113~132 (2000)[DOI]
54. Seo BS, "Anthelmintic efficacy of methyl-5-benzoylbenzimidazle-2-carbamate (mebendazole)against multiple helminthic infections", Korean J Parasitol, 15, pp.11~16 (1977)[DOI]
55. Sinniah B, "Collected Papers on the Control of Soil-Transmitted Helminthiases by Asian Parasite Control Organization (APCO)", pp.321~325 (1980), The Asian Parasite Control Organization
56. Coulaud JP, Duchatelle C, Rouvillois A, Deluol AM, "Le Zentel®dans le traitement des helminthiases intestinales, au Niger, en Guinée et à Paris", Méd Afr Noire, 29, pp.41~42 (1982)
57. Kim CH, "Clinical trials of mebendazole (Vermox) on Ascaris and Trichuris infection", Chungnam Med J, 2, pp.207~211 (1975)
58. Seo BS, "Efficacy of mebendazole in treatment and control of trichuriasis in Korea", Korean J Parasitol, 21, pp.95~101 (1983)
59. Henriquez-Camacho C, "Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection", Cochrane Datab Syst Rev, 2016, pp.CD007745~ (2016)[DOI]
60. Hong SJ, "A case of Strongyloides stercoralis infection", Korean J Parasitol, 37, pp.117~120 (1999)[DOI]
61. Echazú A, "Albendazole and ivermectin for control of soiltransmitted helminths in an area with high prevalence of Strongyloides stercoralis and hookworm in northwestern Argentina: a community-based pragmatic study", PLoS Negl Trop Dis, 11, pp.e0006003~ (2017)[DOI]
62. Chai JY, "Anthelmintic effect of albendazole (Alzental@) on human intestinal nematodes", J Korean Soc Chemother, 4, pp.86~88 (1986)
63. St Georgiev V, "Chemotherapy of enterobiasis (oxyuriasis)", Expert Opin Pharmacother, 2, pp.267~275 (2001)[DOI]
64. Cho SY, "Evaluation of anthelmintic treatment on Enterobius vermicularis infection in highly endemic population by prolonged observation", Korean J Parasitol, 15, pp.100~108 (1977)[DOI]
65. Hong ST, "Efficacy of repeated chemotherapy in control of Enterobius vermicularis infection", Seoul J Med, 20, pp.163~168 (1979)
66. Steinmann P, "Tribendimidine and albendazole for treating soil-transmitted helminths, Strongyloides stercoralis and Taenia spp.: open-label randomized trial", PLoS Negl Trop Dis, 2, pp.e322~ (2008)[DOI]
67. Soh CT, "Clinical trial of Vermox (mebendazole), a new broadspectrum anthelmintic", Yonsei Rep Trop Med, 5, pp.148~152 (1974)
68. Chavarria AP, "Mebendazole in the treatment of taeniasis solium and taeniasis saginata", Am J Trop Med Hyg, 26, pp.118~120 (1977)[DOI]
69. 채종일, "Praziquantel Treatment in Trematode and Cestode Infections: An Update", Infection and Chemotherapy, 45(1), pp.32~43 (2013), 대한감염학회[DOI]
70. Rossignol JF, "Albendazole: placebo-controlled study in 870 patients with intestinal helminthiasis", Trans R Soc Trop Med Hyg, 77, pp.707~711 (1983)[DOI]
71. Keystone JS, "Mebendazole", Ann Intern Med, 91, pp.582~586 (1979)
72. Kong L, "Adv Parasitol", Adv Parasitol, 109, pp.433~448 (2020)[DOI]
73. Nicholas WL, "The action of benzimidazoles on the larval stage of Toxocara canis in the mouse", Ann Trop Med Parasitol, 73, pp.57~62 (1979)[DOI]
74. Stürchler D, "albendazole in treatment of toxocariasis : a clinical trial", Ann Trop Med Parasitol 1989;, 83, pp.473~478 (1989)[DOI]
75. Barisani-Asenbauer T, "Treatment of ocular toxocariasis with albendazole", J Ocul Pharmacol Therapeut, 17, pp.287~294 (2001)[DOI]
76. Anonymous, "Drugs for parasitic infections", Med Lett Drugs Ther, 1189, pp.1~12 (2004)
77. Singer OC, "Severe meningoencephalomyelitis due to CNS-toxocarosis", J Neurol, 258, pp.696~698 (2011)[DOI]
78. Feske SK, "Case 29-2015: a 38-year-old pregnant woman with headache and visual symptoms", N Engl J Med, 373, pp.1154~1164 (2015)[DOI]
79. Melliou M, "Toxocariasis of the nervous system", Acta Parasitol, 65, pp.291~299 (2020)[DOI]
80. Hombu A, "Treatment of larva migrans syndrome with longterm administration of albendazole", J Microbiol Immunol Infect, 52, pp.100~105 (2019)[DOI]
81. Magnaval JF, "Comparative efficacy of diethylcarbamazine and mebendazole for treatment of human toxocariasis", Parasitology, 110, pp.529~533 (1995)[DOI]
82. Coulaud JP, "Treatment of cutaneous larva migrans “Larbish’ with albendazole: report of 18 cases", Bull Soc Pathol Exot Filiales, 75, pp.534~537 (1982)
83. Thadchanamoorthy V, "Cutaneous larvae migrans infestation over buttocks and perianal region: a case series of five toddlers from Sri Lanka and literature review", Cureus, 12, pp.e11335~ (2020)[DOI]
84. Mulia RC, "Office-made 4% albendazole cream is an effective alternative therapy for cutaneous larva migrans: a report of three cases", Serbian J Dermatol Venerol, 12, pp.9~13 (2020)[DOI]
85. Tan SK, "Cutaneous larva migrans complicated by Löffler syndrome", Arch Dermatol, 146, pp.210~212 (2010)[DOI]
86. Sohn WM, "Oxford Textbook of Zoonoses: Biology, Clinical Practice, and Public Health Control", pp.776~788 (2011), Oxford Univ Press
87. Lim H, "Molecular diagnosis of cause of anisakiasis in humans, South Korea", Emerg Infect Dis, 21, pp.342~344 (2015)[DOI]
88. Moore DAJ, "Treatment of anisakiasis with albendazole", Lancet, 360, pp.54~ (2002)[DOI]
89. Pacios E, "Albendazole for the treatment of anisakiasis ileus", Clin Infect Dis, 41, pp.1825~1826 (2005)[DOI]
90. Baptista-Fernandes T, "Human gastric hyperinfection by Anisakis simplex: a severe and unusual presentation and a brief review", Int J Infect Dis, 64, pp.38~41 (2017)[DOI]
91. Guardone L, "Human anisakiasis in Italy : a retrospective epidemiological study over two decades", Parasite, 25, pp.41~ (2018)[DOI]
92. Maggi P, "Gastrointestinal infection due to Anisakis simplex in southern Italy", Eur J Epidemiol, 16, pp.75~78 (2000)[DOI]
93. Moschella CM, "Intestinal anisakiasis in Italy: case report", J Helminthol, 78, pp.271~273 (2004)[DOI]
94. Gómez-Mateos M, "Acute anisakiasis : pharmacological evaluation of various drugs", Dig Dis Sci, 66, pp.105~113 (2021)[DOI]
95. McCracken RO, "Efficacy of mebendazole and albendazole against Trichinella spiralis in mice", J Parasitol, 64, pp.214~219 (1978)[DOI]
96. Fourestié V, "Randomized trial of albendazole versus tiabendazole plus flubendazole during an outbreak of human trichinellosis", Parasitol Res, 75, pp.36~41 (1988)[DOI]
97. Cabié A, "Albendazole versus thiabendazole as therapy for trichinosis : a retrospective study", Clin Infect Dis, 22, pp.1033~1035 (1996)[DOI]
98. Gottstein B, "Epidemiology, diagnosis, treatment, and control of trichinellosis", Clin Microbiol Rev, 22, pp.127~145 (2009)[DOI]
99. Dupouy-Camet J, "Opinion on the diagnosis and treatment of human trichinellosis", Expert Opin Pharmacother, 3, pp.1117~1130 (2002)[DOI]
100. Bruschi F, "Hunter’s Tropical Medicine and Emerging Infectious Diseases", pp.882~884 (2000), Saunders
101. Maria L López-Garcı́a, "Methimazole-mediated enhancement of albendazole oral bioavailability and anthelmintic effects against parenteral stages of Trichinella spiralis in mice: the influence of the dose-regime", Veterinary Parasitology, 75(2-3), pp.209~219 (1998), Elsevier BV[DOI]
102. Kalaiselvan R, "Enhancement of bioavailability and anthelmintic efficacy of albendazole by solid dispersion and cyclodextrin complexation techniques", Pharmazie, 62, pp.604~607 (2007)[DOI]
103. Rania K. Eid, "Chitosan coated nanostructured lipid carriers for enhanced in vivo efficacy of albendazole against Trichinella spiralis", Carbohydrate Polymers, 232, pp.115826~ (2020), Elsevier BV
104. Sujatha S. E. Fernando, "The Effects of Mebendazole and Fenbendazole on Trichinella spiralis in Mice", The Journal of Parasitology, 62(6), pp.874~876 (1976), JSTOR[DOI]
105. J.J. Sonnet, "The Treatment of Trichinosis with Mebendazole", Acta Clinica Belgica, 32(5), pp.297~302 (2016), Informa UK Limited[DOI]
106. Levin ML, "Treatment of trichinosis with mebendazole", Am J Trop Med Hyg, 32, pp.980~983 (1983)[DOI]
107. Pozio E, "Failure of mebendazole in the treatment of humans with Trichinella spiralis infection at the stage of encapsulating larvae", Clin Infect Dis, 32, pp.638~642 (2001)[DOI]
108. Cheetham RF, "Drug treatment of experimental Capillaria hepatica infection in mice", Parasitol Res, 77, pp.517~520 (1991)[DOI]
109. Choe GY, "Hepatic capillariasis: first case report in Korea", Am J Trop Med Hyg, 48, pp.610~625 (1993)[DOI]
110. 110. Sawamura R, "Hepatic capillariasis in children : report of 3 cases in Brazil", Am J Trop Med Hyg 1999;, 61, pp.642~647 (1999)[DOI]
111. Abhishek Dubey, "Hepatic Capillariasis- Drug Targets", Infectious Disorders - Drug Targets, 18(1), pp.3~10 (2018), Bentham Science Publishers Ltd.[DOI]
112. Cross JH, "Albendazole in the treatment of intestinal capillariasis", Southeast Asian J Trop Med Public Health, 18, pp.507~510 (1987)
113. Byung Ihn Choi, "A Case of Intestinal Capillariasis in the Republic of Korea", The American Journal of Tropical Medicine and Hygiene, 48(4), pp.542~546 (1993), American Society of Tropical Medicine and Hygiene[DOI]
114. Hong ST, "Two cases of intestinal capillariasis in Korea", Korean J Parasitol, 32, pp.43~48 (1994)[DOI]
115. Bair MJ, "Clinical features of human intestinal capillariasis in Taiwan", World J Gastroenterol, 10, pp.2391~2393 (2004)[DOI]
116. Kongsap Akkhavong, "Three Cases of Intestinal Capillariasis in Lao People’s Democratic Republic", The American Journal of Tropical Medicine and Hygiene, 79(5), pp.735~738 (2008), American Society of Tropical Medicine and Hygiene[DOI]
117. Rana SS, "Human intestinal capillariasis: diagnosis by jejunal fluid analysis obtained at enteroscopy and reversal of subtotal villous atrophy after treatment", Endoscopy, 41(suppl), pp.102~103 (2009)[DOI]
118. Sadaow L, "A hospital-based study of intestinal capillariasis in Thailand: clinical features, potential clues for diagnosis, and epidemiological characteristics of 85 patients", Am J Trop Med Hyg, 98, pp.27~31 (2018)[DOI]
119. Alcantara AK, "An obstinate case of intestinal capillariasis", Southeast Asian J Trop Med Public Health, 16, pp.410~413 (1985)
120. Hoghooghi-Rad N, "Capillaria philippinensis infection in Khoozestan province, Iran: case report", Am J Trop Med Hyg, 37, pp.135~137 (1987)[DOI]
121. Dronda F, "Human intestinal capillariasis in an area of nonendemicity: case report and review", Clin Infect Dis, 17, pp.909~912 (1993)[DOI]
122. N.S. Mansour, "Human intestinal capillariasis in Egypt", Transactions of the Royal Society of Tropical Medicine and Hygiene, 84(1), pp.114~ (1990), Oxford University Press (OUP)[DOI]
123. Hwang KP, "Clinical studies on angiostrongyliasis cantonensis among children in Taiwan", Southeast Asian J Trop Med Public Health, 22(suppl), pp.194~199 (1991)
124. Wang X, "A clinical study of eosinophilic meningoencephalitis caused by angiostrongyliasis", Chin Med J, 115, pp.1312~1315 (2002)
125. Chotmongkol V, "Treatment of eosinophilic meningitis with a combination of albendazole and corticosteroid", Southeast Asian J Trop Med Public Health, 35, pp.172~174 (2004)
126. Wang J, "An outbreak of angiostrongyliasis cantonensis in Beijing", J Parasitol, 96, pp.377~381 (2010)[DOI]
127. Federspiel F, "Eosinophilic meningitis due to Angiostrongylus cantonensis in Europe", Int J Infect Dis, 93, pp.28~39 (2020)[DOI]
128. Tsai HC, "Eosinophilic meningitits caused by Angiostrongylus cantonensis: report of 17 cases", Am J Med, 111, pp.109~114 (2001)[DOI]
129. Chotmongkol V, "Treatment of eosinophilic meningitis with a combination of prednisolone and mebendazole", Am J Trop Med Hyg, 74, pp.1122~1124 (2006)[DOI]
130. Sebastiano Leone, "Eosinophilic Meningitis in a Returned Traveler From Santo Domingo: Case Report and Review", Journal of Travel Medicine, 14(6), pp.407~410 (2007), Oxford University Press (OUP)[DOI]
131. C.C. Hermes, "Abdominal angiostrongyliasis: pathologic findings in Swiss mice infected with different doses of Angiostrongylus costaricensis", Journal of Helminthology, 94, pp.e169~ (2020), Cambridge University Press (CUP)[DOI]
132. Dekumyoy P, "Hunter’s Tropical Medicine and Emerging Infectious Diseases", pp.888~890 (2020), Elsevier
133. Kraivichian K, "Albendazole for the treatment of human gnathostomiasis", Trans R Soc Trop Med Hyg, 86, pp.418~442 (1992)[DOI]
134. Nontasut P, "Comparison of ivermectin and albendazole treatment for gnathostomiasis", Southeast Asian J Trop Med Public Health, 31, pp.374~377 (2000)[DOI]
135. Nontasut P, "Double-dose ivermectin vs albendazole for the treatment of gnathostomiasis", Southeast Asian J Trop Med Public Health, 36, pp.650~652 (2005)
136. Kraivichian K, "Treatment of cutaneous gnathostomiasis with ivermectin", Am J Trop Med Hyg, 71, pp.623~628 (2004)[DOI]
137. Vidal Haddad Junior, "Gnathostomiasis acquired after consumption of raw freshwater fish in the Amazon region: a report of two cases in Brazil", Revista da Sociedade Brasileira de Medicina Tropical, 54, pp.e20200127~ (2021), FapUNIFESP (SciELO)[DOI]
138. Chai JY, "An outbreak of gnathostomiasis among Korean emigrants in Myanmar", Am J Trop Med Hyg, 69, pp.67~73 (2003)[DOI]
139. Vanegas ES, "A 41-year-old woman with migratory panniculitis", Am J Trop Med Hyg, 90, pp.786~787 (2014)[DOI]
140. Sharma C, "Case report:clinical features of intermittent migratory swelling caused by gnathostomiasis with complete follow-up", Am J Trop Med Hyg, 97, pp.1611~1615 (2017)[DOI]
141. Herman JS, "Gnathostomiasis, another emerging imported disease", Clin Microbiol Rev, 2(22), pp.484~492 (2009)[DOI]
142. Raharisoa A, "Autochthonous gnathostomiasis in Madagascar", Emerg Infect Dis, 26, pp.1875~1877 (2020)[DOI]
143. M L Eberhard, "Human Gongylonema infection in a resident of New York City.", The American Journal of Tropical Medicine and Hygiene, 61(1), pp.51~52 (1999), American Society of Tropical Medicine and Hygiene[DOI]
144. Wilson ME, "Gongylonema infection of the mouth in a resident of Cambridge, Massachusetts", Clin Infect Dis, 32, pp.1378~1380 (2001)[DOI]
145. Marco Antonio Ayala, "Gongylonema a parasitic nematode of the oral cavity", Arch Otolaryngol Head Neck Surg, 138(11), pp.1082~1084 (2012), American Medical Association (AMA)[DOI]
146. Waisberg V, "Intraocular Gongylonema infection: first case in humans", Ocul Immunol Inflam, 26, pp.595~597 (2016)[DOI]
147. Liu Xiaodan, "Gongylonema pulchrum infection in the human oral cavity: A case report and literature review", Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 125(3), pp.e49~e53 (2018), Elsevier BV[DOI]
148. Libertin CR, "Human Gongylonema pulchrum infection: esophageal symptoms and need for prolonged albendazole therapy", Am J Trop Med Hyg, 96, pp.873~875 (2017)[DOI]
149. Noboru Kudo, "Efficacy of thiabendazole, mebendazole, levamisole and ivermectin against gullet worm, Gongylonema pulchrum: In vitro and in vivo studies", Veterinary Parasitology, 151(1), pp.46~52 (2008), Elsevier BV[DOI]
150. Beatriz do Vale, "Thelaziosis due to Thelazia callipaeda in Europe in the 21st century—A review", Veterinary Parasitology, 275, pp.108957~ (2019), Elsevier BV[DOI]
151. Rafael Calero-Bernal, "Resolution of canine ocular thelaziosis in avermectin-sensitive Border Collies from Spain", Veterinary Parasitology, 200(1-2), pp.203~206 (2014), Elsevier BV[DOI]
152. Meenakshi Sharma, "Human ocular thelaziasis caused by gravid Thelazia callipaeda – A unique and rare case report", Indian Journal of Ophthalmology, 67(2), pp.282~285 (2019), Medknow[DOI]
153. A. Mullner, "Chemistry and Pharmacology of Neglected Helminthic Diseases", Current Medicinal Chemistry, 18(5), pp.767~789 (2011), Bentham Science Publishers Ltd.[DOI]
154. Mark L. Eberhard, "Chemoprophylactic drug trials for treatment of dracunculiasis using the Dracunculus insignis-ferret model", Journal of Helminthology, 64(2), pp.79~86 (1990), Cambridge University Press (CUP)[DOI]
155. Escobedo F, "Albendazole therapy for neurocysticercosis", Arch Intern Med, 147, pp.738~741 (1987)[DOI]
156. Sotelo J, "Albendazole vs praziquantel for therapy for neurocysticercosis", A controlled trial. Arch Neurol, 45, pp.532~553 (1988)[DOI]
157. Alarcón F, "Neurocysticercosis. Short course of treatment with albendazole", Arch Neurol, 46, pp.1231~1236 (1989)[DOI]
158. Sotelo J, "Pharmacokinetic optimization of the treatment of neurocysticercosis", Clin Pharmacokinet, 34, pp.503~515 (1998)[DOI]
159. García HH, "Current consensus guidelines for treatment of neurocysticercosis", Clin Microbiol Rev, 15, pp.747~756 (2002)[DOI]
160. del Brutto OH, "Albendazole therapy for subarachnoid and ventricular cysticercosis-case report", J Neurosurg, 72, pp.816~817 (1990)
161. Arroyo G, "Albendazole sulfoxide plasma levels and efficacy of antiparasitic treatment in patients with parenchymal neurocysticercosis", Clin Infect Dis, 69, pp.1996~2002 (2019)[DOI]
162. Schmidt DK, "Cerebral and subcutaneous cysticercosis treated with albendazole", Int J Dermatol, 34, pp.574~579 (1995)[DOI]
163. Surve A, "Extraocular muscle cysticercosis: never skip steroids", BMJ Case Rep, 2018, pp.1~2 (2018)[DOI]
164. Palomares-Alonso F, "Effect of dexamethasone on albendazole cysticidal activity in experimental cysticercosis by Taenia crassiceps in BALB", c mice: in vivo and in vitro evaluation, 2020, pp.208, 107801~
165. Cook GC, "Use of benzimidazole chemotherapy in human helminthiases: indications and efficacy", Parasitol Today, 6, pp.133~136 (1990)[DOI]
166. Heath DD, "The lethal effect of mebendazole on secondary Echinococcus granulosus, cysticerci of Taenia pisiformis and tetrathyridia of Mesocestoides corti", Parasitology, 70, pp.273~285 (1975)[DOI]
167. Francisca PA, "Cysticidal activity of praziquantel-mebendazole combination: in vitro and in vivo studies", Acta Trop, 202, pp.105238~ (2019)[DOI]
168. Hemphill A, "Treatment of echinococcosis: albendazole and mebendazole-what else?", Parasite, 21, pp.70~ (2014)[DOI]
169. Virginia Velasco-Tirado, "Medical treatment of cystic echinococcosis: systematic review and meta-analysis", BMC Infectious Diseases, 18(1), pp.306~ (2018), Springer Science and Business Media LLC[DOI]
170. Saimot AG, "Albendazole as a potential treatment for human hydatidosis", Lancet, 322, pp.652~656 (1983)[DOI]
171. Morris DL, "Albendazole in hydatid disease", Br Med J, 286, pp.103~104[DOI]
172. Todorov T, "Chemotherapy of human cystic echinococcosis: comparative efficacy of mebendazole and albendazole", Ann Trop Med Parasitol, 86, pp.59~66 (1992)[DOI]
173. Horton RJ, "Albendazole in treatment of human cystic echinococcosis: 12 years of experience", Acta Trop, 64, pp.79~93 (1997)[DOI]
174. Horton J, "Albendazole for the treatment of echinococcosis", Fundam Clin Pharmacol, 17, pp.205~212 (2003)[DOI]
175. Falagas ME, "Albendazole for the treatment of human echinococcosis: a review of comparative clinical trials", Am J Med Sci, 334, pp.171~179 (2007)[DOI]
176. Mohamed AE, "Combined albendazole and praziquantel versus albendazole alone in the treatment of hydatid disease", Hepatogastroenterology, 45, pp.1690~1694 (1998)
177. Cobo F, "Albendazole plus praziquantel versus albendazole alone as a pre-operative treatment in intra-abdominal hydatidosis caused by Echinococcus granulosus", Trop Med Int health, 3, pp.462~466 (1998)[DOI]
178. Mueller PR, "Hepatic echinococcal cyst: successful percutaneous drainage", Radiology, 15, pp.627~628 (1985)[DOI]
179. Khuroo MS, "Percutaneous drainage versus albendazole therapy in hepatic hydatidosis: a prospective, randomized study", Gastroenterology, 104, pp.1452~1459 (1993)[DOI]
180. Khuroo MS, "Percutaneous drainage compared with surgery for hepatic hydatid cysts", N Engl J Med, 337, pp.881~887 (1997)[DOI]
181. Smego RA Jr, "Percutaneous aspiration-injection-reaspiration drainage plus albendazole or mebendazole for hepatic cystic echinococcosis: a meta-analysis", Clin Infect Dis, 37, pp.1073~1083 (2003)[DOI]
182. Örmeci N, "Percutaneous treatment with the Örmeci technique of cystic echinococcosis: experience of single center", Gastroenterol Hepatol Open Access, 11, pp.223~230 (2020)[DOI]
183. Heath DD, "Mebendazole and hydatid cysts", Lancet, 304, pp.218~219 (1974)[DOI]
184. Bekhti A, "Treatment of hepatic hydatid disease with mebendazole:preliminary results in four cases", Br Med J, 2, pp.1047~1051 (1977)[DOI]
185. Verheyen A, "Echinococcus granulosus: the influence of mebendazole therapy on the ultrastructural morphology of the germinal layer of hydatid cysts in humans and mice", Z Parazitenkd, 67, pp.55~65 (1982)[DOI]
186. Göçmen A, "Treatment of hydatid disease in childhood with mebendazole", Eur Respir J, pp.253~257 (1993)[DOI]
187. Salto E, "Combined chemotherapy (mebendazole plus praziquantel) in patients with hydatidosis", Enferm Infecc Microbiol Clin, 9, pp.527~529 (1991)
188. Vutova K, "Effect of mebendazole on human cystic echinococcosis: the role of dosage and treatment duration", Ann Trop Med Parasitol, 93, pp.357~365 (1999)[DOI]
189. Ammann RW, "Long-term mebendazole therapy may be parasitocidal in alveolar echinococcosis", J Hepatol, 29, pp.994~998 (1998)[DOI]
190. David Addiss, "Albendazole for lymphatic filariasis", Cochrane Database of Systematic Reviews, 4, pp.CD003753~ (2005), Wiley[DOI]
191. Kimura E, "The efficacy of annual single-dose treatment with diethylcarbamazine citrate against diurnally subperiodic bancroftian filariasis in Samoa", Bull World Health Organ, 63, pp.1097~1106 (1985)
192. E.A. Ottesen, "The Role of Albendazole in Programmes to Eliminate Lymphatic Filariasis", Parasitology Today, 15(9), pp.382~386 (1999), Elsevier BV[DOI]
193. Moulia-Pelat JP, "Combination ivermectin plus diethylcarbamazine, a new effective tool for control lymphatic filariasis", Trop Med Parasitol, 46, pp.9~12 (1995)
194. Jayakody RL, "Treatment of bancroftian filariasis with albendazole: evaluation of efficacy and adverse reactions", Trop Biomed, 10, pp.19~24 (1993)
195. Addiss DA, "Randomised placebo-controlled comparison of ivermectin and albendazole and in combination for Wuchereria bancrofti microfilaraemia in Haitian children", Lancet, 350, pp.480~484 (1997)[DOI]
196. M.M. Ismail, "Efficacy of single dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis", Transactions of the Royal Society of Tropical Medicine and Hygiene, 92(1), pp.94~97 (1998), Oxford University Press (OUP)[DOI]
197. J. Horton, "The development of albendazole for lymphatic filariasis", Annals of Tropical Medicine & Parasitology, 103(sup1), pp.33~40 (2013), Informa UK Limited[DOI]
198. Sébastien D. S. Pion, "The impact of four years of semiannual treatments with albendazole alone on lymphatic filariasis and soil-transmitted helminth infections: A community-based study in the Democratic Republic of the Congo", PLOS Neglected Tropical Diseases, 14(6), pp.e0008322~ (2020), Public Library of Science (PLoS)[DOI]
199. Ottesen EA, "Strategies and tools for the control", elimination of lymphatic filariasis, 1997, pp.75, 491~503
200. R. K. Shenoy, "Treatment of the microfilaraemia of asymptomatic brugian filariasis with single doses of ivermectin, diethylcarbamazine or albendazole, in various combinations", Annals of Tropical Medicine & Parasitology, 93(6), pp.643~651 (2016), Informa UK Limited[DOI]
201. Peter Fischer, "Long-lasting reduction of Brugia timori microfilariae following a single dose of diethylcarbamazine combined with albendazole", Transactions of the Royal Society of Tropical Medicine and Hygiene, 97(4), pp.446~448 (2003), Oxford University Press (OUP)[DOI]
202. John O Gyapong, "Treatment strategies underpinning the global programme to eliminate lymphatic filariasis", Expert Opinion on Pharmacotherapy, 6(2), pp.179~200 (2005), Informa UK Limited[DOI]
203. Tisch DJ, "Mass chemotherapy options to control lymphatic filariasis: a systematic review", Lancet Infect Dis, 5, pp.514~523 (2005)[DOI]
204. Critchley J, "Albendazole for the control and elimination of lymphatic filariasis : systematic review", Trop Med Int Health, 10, pp.818~825 (2005)[DOI]
205. Macfarlane CL, "Albendazole along or in combination with microfilaricidal drugs for lymphatic filariasis (Review)", Cochrane Datab Syst Rev, 1, pp.CD003753~ (2019)[DOI]
206. Shantanu K. Kar, "Lymphatic pathology in asymptomatic and symptomatic children with Wuchereria bancrofti infection in children from Odisha, India and its reversal with DEC and albendazole treatment", PLOS Neglected Tropical Diseases, 11(10), pp.e0005631~ (2017), Public Library of Science (PLoS)[DOI]
207. Constant Edi, "Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Côte d’Ivoire", PLOS Neglected Tropical Diseases, 13(5), pp.e0007325~ (2019), Public Library of Science (PLoS)[DOI]
208. Purushothaman Jambulingam, "An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India", PLOS Neglected Tropical Diseases, 15(2), pp.e0009069~ (2021), Public Library of Science (PLoS)[DOI]
209. J. D. Turner, "A Randomized, Double-Blind Clinical Trial of a 3-Week Course of Doxycycline plus Albendazole and Ivermectin for the Treatment of Wuchereria bancrofti Infection", Clinical Infectious Diseases, 42(8), pp.1081~1089 (2006), Oxford University Press (OUP)[DOI]
210. Sarma RVSN, "Use of mebendazole in combination with DEC in bancroftian filariasis", Indian J Med Res, 87, pp.579~583 (1988)
211. K. Awadzi, "The co-administration of ivermectin and albendazole-safety, pharmacokinetics and efficacy against Onchocerca volvulus", Annals of Tropical Medicine & Parasitology, 97(2), pp.165~178 (2013), Informa UK Limited[DOI]
212. Awadzi K, "The chemotherapy of onchocerciasis. XV. Studies with albendazole", Trop Med Parasitol, 42, pp.356~360 (1991)
213. Sara Rodulfo, "Albendazole in the Treatment of Onchocerciasis: Double-Blind Clinical Trial in Venezuela", The American Journal of Tropical Medicine and Hygiene, 47(4), pp.512~520 (1992), American Society of Tropical Medicine and Hygiene[DOI]
214. Awadzi K, "The chemotherapy of onchocerciasis. XX. Ivermectin in combination with albendazole", Trop Med Parasitol, 46, pp.213~220 (1995)
215. Batsa Debrah L, "Comparison of repeated doses of ivermectin versus ivermectin plus albendazole for the treatment of onchocerciasis: a randomized, open-label, clinical trial", Clin Infect Dis, 71, pp.933~943 (2020)[DOI]
216. Mark J Taylor, "Lymphatic filariasis and onchocerciasis", The Lancet, 376(9747), pp.1175~1185 (2010), Elsevier BV[DOI]
217. Klarmann-Schulz U, "Comparison of doxycycline, minocycline, doxycycline plus albendazole and albendazole alone in their efficacy against onchocerciasis in a randomized, open-label, pilot trial", PLoS Negl Trop Dis, 11, pp.e0005156~ (2017)[DOI]
218. Fischer PU, "Potential value of triple drug therapy with ivermectin, diethylcarbamazine, and albendazole (IDA) to accelerate elimination of lymphatic filariasis and onchocerciasis in Africa", PLoS Negl Trop Dis, 11, pp.e0005163~ (2017)[DOI]
219. B.O.L. Duke, "Mebendazole-ineffective against Onchocerca volvulus", Transactions of the Royal Society of Tropical Medicine and Hygiene, 68(2), pp.172~ (1974), Oxford University Press (OUP)[DOI]
220. Karel Maertens, "Effect of mebendazole and levamisole on Onchocerca volvulus and Dipetalonema perstans", Transactions of the Royal Society of Tropical Medicine and Hygiene, 69(3), pp.359~360 (1975), Oxford University Press (OUP)[DOI]
221. Taylor HR, "Fluorescein angiographic studies of mebendazole treatment for onchocerciasis", Trop Med Parasitol, 36, pp.7~11 (1985)
222. A.R. Rivas-Alcalá, "CHEMOTHERAPY OF ONCHOCERCIASIS: A CONTROLLED COMPARISON OF MEBENDAZOLE, LEVAMISOLE, AND DIETHYLCARBAMAZINE", The Lancet, 318(8245), pp.485~490 (1981), Elsevier BV[DOI]
223. K. Awadzi, "The chemotherapy of onchocerciasis VIII", Annals of Tropical Medicine & Parasitology, 76(4), pp.459~473 (2016), Informa UK Limited[DOI]
224. K. Awadzi, "Research notes from the Onchocerciasis Chemotherapy Research Centre, Ghana", Annals of Tropical Medicine & Parasitology, 91(7), pp.703~711 (2016), Informa UK Limited[DOI]
225. Awadzi K, "The safety, tolerability and pharmacokinetics of levamisole alone, levamisole plus ivermectin, and levamisole plus albendazole, and their efficacy against Onchocerca volvulus", Ann Trop Med Parasitol, 98, pp.595~614 (2004)[DOI]
226. Klion AD, "Albendazole in human loiasis: results of a double-blind, placebo-controlled trial", J Infect Dis, 168, pp.202~206 (1993)[DOI]
227. Klion AD, "Albendazole therapy for loiasis refractory to diethylcarbamazine treatment", Clin Infect Dis, 2, pp.680~682 (1999)[DOI]
228. Divine B. Arrey-Agbor, "Case Report: Probable Case of Spontaneous Encephalopathy Due to Loiasis and Dramatic Reduction of Loa loa Microfilariaemia with Prolonged Repeated Courses of Albendazole", The American Journal of Tropical Medicine and Hygiene, 99(1), pp.112~115 (2018), American Society of Tropical Medicine and Hygiene[DOI]
229. Federico Gobbi, "Efficacy of High-Dose Albendazole with Ivermectin for Treating Imported Loiasis, Italy", Emerging Infectious Diseases, 25(8), pp.1574~1576 (2019), Centers for Disease Control and Prevention (CDC)[DOI]
230. Tabi TE, "Human loiasis in a Cameroonian village: a double-blind, placebo-controlled, crossover clinical trial of a three-day albendazole regimen", Am J Trop Med Hyg, 71, pp.211~215 (2004)[DOI]
231. L. Tsague-Dongmo, "Effects of a 3-day regimen of albendazole (800 mg daily)on Loa loa microfilaraemia", Annals of Tropical Medicine & Parasitology, 96(7), pp.707~715 (2013), Informa UK Limited[DOI]
232. Richard-Lenoble D, "Filariasis in Gabon: treatment with mebendazole of filariasis due to Mansonella perstans and Loa loa", Bull Soc Pathol Rxot Filial, 78, pp.485~491 (1985)
233. urchard GD, "Failure of high dose mebendazole as a microfilaricide in patients with loiasis", Trans R Soc Trop Med Hyg, 81, pp.420~ (1987)[DOI]
234. M. Van Hoegaerden, "The use of mebendazole in the treatment of filariasis due to Loa loa and Mansonella perstans", Annals of Tropical Medicine & Parasitology, 81(3), pp.275~282 (2016), Informa UK Limited[DOI]
235. Kamgno J, "Effect of a single dose (600 mg) of albendazole on Loa loa microfilaraemia", Parasite, 9, pp.59~63 (2002)[DOI]
236. Pion S, "Arthropod Borne Diseases", pp.427~444 (2017), Springer
237. Ta-Tang TH, "Mansonellosis: current perspectives", Res Rep Trop Med, 9, pp.9~24 (2018)[DOI]
238. Sabino Puente, "Imported Mansonella perstans infection in Spain", Infectious Diseases of Poverty, 9(1), pp.105~ (2020), Springer Science and Business Media LLC[DOI]
239. Van den Enden E, "Mansonella perstans filariasis: failure of albendazole treatment", Ann Soc Belge Med Trop, 72, pp.215~218 (1992)
240. Filippo Lipani, "Albendazole for the treatment of Mansonella perstans filariasis", Transactions of the Royal Society of Tropical Medicine and Hygiene, 91(2), pp.221~ (1997), Oxford University Press (OUP)[DOI]
241. Thanh Hai Duong, "Decrease in Mansonella perstans microfilaraemia after albendazole treatment", Transactions of the Royal Society of Tropical Medicine and Hygiene, 92(4), pp.459~ (1998), Oxford University Press (OUP)[DOI]
242. S. M. Asio, "Mansonella perstans: safety and efficacy of ivermectin alone, albendazole alone and the two drugs in combination", Annals of Tropical Medicine & Parasitology, 103(1), pp.31~37 (2013), Informa UK Limited[DOI]
243. Asgeirsson H, "Successful treatment of 2 imported cases of Mansonella perstans infection", PLoS Negl Trop Dis, 11, pp.e0005452~ (2017)[DOI]
244. Linda Batsa Debrah, "The Efficacy of Doxycycline Treatment on Mansonella perstans Infection: An Open-Label, Randomized Trial in Ghana", The American Journal of Tropical Medicine and Hygiene, 101(1), pp.84~92 (2019), American Society of Tropical Medicine and Hygiene[DOI]
245. M. Wahlgren, "The successful treatment of Dipetalonema perstans filariasis with mebendazole", Annals of Tropical Medicine & Parasitology, 76(5), pp.557~559 (2016), Informa UK Limited[DOI]
246. Wahlgren M, "Treatment of Dipetalonema perstans infections with mebendazole", Trans R Soc Trop Med Hyg, 77(3), pp.422~423 (1983), Oxford University Press (OUP)[DOI]
247. Enrico Rino Bregani, "Comparison of different anthelminthic drug regimens against Mansonella perstans filariasis", Transactions of the Royal Society of Tropical Medicine and Hygiene, 100(5), pp.458~463 (2006), Oxford University Press (OUP)[DOI]
248. Fernando Simón, "Human and Animal Dirofilariasis: the Emergence of a Zoonotic Mosaic", Clinical Microbiology Reviews, 25(3), pp.507~544 (2012), American Society for Microbiology[DOI]
249. GheorghiŢă MI, "Intramuscular human Dirofilaria repens infection of the temporal region-case report and review of literature", Rom J Morphol Embryol, 58, pp.585~592 (2017)
250. Larisa Ermakova, "Clinical and laboratory features of human dirofilariasis in Russia", IDCases, 9, pp.112~115 (2017), Elsevier BV[DOI]
251. Tatyana V. Moskvina, "Dirofilariasis in Russian Federation: a big problem with large distribution", Russian Open Medical Journal, 7(1), pp.e0102~ (2018), LLC Science and Innovations[DOI]
252. Jennifer Keiser, "Triclabendazole for the treatment of fascioliasis and paragonimiasis", Expert Opinion on Investigational Drugs, 14(12), pp.1513~1526 (2005), Informa UK Limited[DOI]
253. Mas-Coma S, "Fascioliasis", Adv Exp Med Biol, 1154, pp.71~103 (2019)[DOI]
254. Ronald NC, "A controlled evaluation of albendazole against natural infections with Fasciola hepatica and Fascioloides magna in cattle", Am J Vet Res, 40, pp.1299~1300 (1979)
255. Raymond Fetterer, "Comparative efficacy of albendazole against Fasciola hepatica in sheep and calves: Relationship to serum drug metabolites levels", Veterinary Parasitology, 11(4), pp.309~316 (1982), Elsevier BV[DOI]
256. P. P. Laird, "Human fascioliasis successfully treated with triclabendazole", Australian and New Zealand Journal of Medicine, 22(1), pp.45~47 (1992), Wiley[DOI]
257. Flavio Vega, "Treatment of Human Chronic Fascioliasis with Triclabendazole: Drug Efficacy and Serologic Response", The American Journal of Tropical Medicine and Hygiene, 52(6), pp.532~535 (1995), American Society of Tropical Medicine and Hygiene[DOI]
258. Mohammad Reza Zali, "Liver, spleen, pancreas and kidney involvement by human fascioliasis: imaging findings", BMC Gastroenterology, 4(1), pp.15~ (2004), Springer Science and Business Media LLC[DOI]
259. R. Saba, "Human fascioliasis", Clinical Microbiology and Infection, 10(5), pp.385~387 (2004), Elsevier BV[DOI]
260. Mark W. Robinson, "The comparative metabolism of triclabendazole sulphoxide by triclabendazole-susceptible and triclabendazole-resistant Fasciola hepatica", Parasitology Research, 92(3), pp.205~210 (2004), Springer Science and Business Media LLC[DOI]
261. Arauco R, "Human fascioliasis: a case of hyperinfection and an update for clinicians", Foodborne Pathog Dis, 4, pp.305~312 (2007)[DOI]
262. Liu YH, "Experimental and clinical trial of albendazole in the treatment of clonorchiasis sinensis", Chin Med J, 104, pp.27~31 (1991)
263. Jaroonvesma N, "Treatment of Opisthorchis viverrini with mebendazole", Southeast Asian J Trop Med Public Health, 12, pp.595~597 (1981)
264. ungpark S, "Albendazole treatment of minute intestinal fluke infections and opisthorchiasis", Parasitol Int, 47(suppl), pp.24~ (1998)[DOI]
265. Cross JH, "Studies on Echinostoma ilocanum in the Philippines", Southeast Asian J Trop Med Public Health, 17, pp.23~27 (1986)
266. Edlind TD, "Activity of the anthelmintic benzimidazoles against Giardia lamblia in vitro", J Infect Dis, 16, pp.1408~1411 (1990)[DOI]
267. Meloni BP, "Albendazole: a more effective antigiardial agent in vitro than metronidazole or tinidazole", Trans R Soc Trop Med Hyg, 84, pp.375~379 (1990)[DOI]
268. Reynoldson JA, "In vivo efficacy of albendazole against Giardia duodenalis in mice", Parasitol Res, 77, pp.325~328 (1991)[DOI]
269. Barr SC, "Efficacy of albendazole against giardiasis in dogs", Am J Vet Res, 54, pp.926~928 (1993)
270. Oxberry ME, "Evaluation of the effects of albendazole and metronidazole on the ultrastructure of Giardia duodenalis, Trichomonas vaginalis and Spironucleus muris using transmission electron microscopy", Int J Parasitol, 24, pp.695~703 (1994)[DOI]
271. Cheng-i W, "Parasitic diarrhoeas in China", Parasitol Today, 4, pp.284~287 (1988)[DOI]
272. Andrew Hall, "Albendazole as a treatment for infections with Giardia duodenalis in children in Bangladesh", Transactions of the Royal Society of Tropical Medicine and Hygiene, 87(1), pp.84~86 (1993), Oxford University Press (OUP)[DOI]
273. Angel A Escobedo, "Management of chronic Giardia infection", Expert Review of Anti-infective Therapy, 12(9), pp.1143~1157 (2014), Informa UK Limited[DOI]
274. Cacopardo B, "Synergic effect of albendazole plus metronidazole association in the treatment of metronidazole-resistant giardiasis", Clin Ther, 146, pp.761~767 (1995)
275. K. Mørch, "Treatment-ladder and genetic characterisation of parasites in refractory giardiasis after an outbreak in Norway", Journal of Infection, 56(4), pp.268~273 (2008), Elsevier BV[DOI]
276. Escobedo AA, "Treatment of refractory paediatric giardiasis using secnidazole plus albendazole: a case series", Infect Med, 26, pp.379~384 (2018)
277. Argüello-García R, "Drug resistance in Giardia: mechanisms and alternative treatments for giardiasis", Adv Parasitol, 107, pp.201~282 (2020)[DOI]
278. J G Hutchison, "Clinical trial of mebendazole, a broad-spectrum anthelminthic.", BMJ, 2(5966), pp.309~310 (1975), BMJ[DOI]
279. Noori S. Al-Waili, "Therapeutic use of mebendazole in giardial infections", Transactions of the Royal Society of Tropical Medicine and Hygiene, 82(3), pp.438~ (1988), Oxford University Press (OUP)[DOI]
280. J. Gascon, "Mebendazole in giardial infections: a reply", Transactions of the Royal Society of Tropical Medicine and Hygiene, 84(5), pp.754~ (1990), Oxford University Press (OUP)[DOI]
281. Al-Waili NS, "Mebendazole in giardial infection: a comparative study with metronidazole", J Infect Dis, 165, pp.1170~1171 (1992)[DOI]
282. S K Katiyar, "Antiprotozoal activities of benzimidazoles and correlations with beta-tubulin sequence", Antimicrobial Agents and Chemotherapy, 38(9), pp.2086~2090 (1994), American Society for Microbiology[DOI]
283. E Brook Goodhew, "Drug library screening against metronidazole-sensitive and metronidazole-resistant Trichomonas vaginalis isolates", Sexually Transmitted Infections, 89(6), pp.479~484 (2013), BMJ[DOI]
284. Juliano C, "In vitro” effect of microtubule inhibitors on Trichomonas vaginalis", Microbiologica, 8, pp.31~42 (1985)
285. Cañete R, "Mebendazole in parasitic infections other than those caused by soil-transmitted helminths", Trans R Soc Trop Med Hyg, 103, pp.437~442 (2009)[DOI]
286. R S Pattman, "Failure of mebendazole to cure trichomonal vaginitis resistant to metronidazole: case reports.", Sexually Transmitted Infections, 65(4), pp.274~275 (1989), BMJ[DOI]
287. Louisa M. MacDonald, "Characterisation of benzimidazole binding with recombinant tubulin from Giardia duodenalis, Encephalitozoon intestinalis, and Cryptosporidium parvum", Molecular and Biochemical Parasitology, 138(1), pp.89~96 (2004), Elsevier BV[DOI]
288. Fayer R, "Activity of benzimidazoles against cryptosporidiosis in neonatal BALB", c mice, 1995, pp.81, 794~795
289. Weiss LM, "Hunter’s Tropical Medicine and Emerging Infectious Diseases", pp.825~831 (2020), Elsevier
290. Christine Blanshard, "Treatment of intestinal microsporidiosis with albendazole in patients with AIDS", AIDS, 6(3), pp.311~313 (1992), Ovid Technologies (Wolters Kluwer Health)[DOI]
291. C J Lacey, "Chronic microsporidian infection of the nasal mucosae, sinuses and conjunctivae in HIV disease.", Sexually Transmitted Infections, 68(3), pp.179~181 (1992), BMJ[DOI]
292. Deplazes P, "Immunologic and molecular characteristics of Encephalitozoon-like microsporidia isolated from humans and rabbits indicate that Encephalitozoon cuniculi is a zoonotic parasite", Clin Infect Dis, 22, pp.557~559 (1996)[DOI]
293. Susan N. Hocevar, "Microsporidiosis Acquired Through Solid Organ Transplantation", Annals of Internal Medicine, 160(4), pp.213~220 (2014), American College of Physicians[DOI]
294. Dore GJ, "Disseminated microsporidiosis due to Septata intestinalis in nine patients infected with the human immunodeficiency virus: response to therapy with albendazole", Clin Infect Dis, 21, pp.70~76 (1995)[DOI]
295. Sunil Dacha, "Microsporidiosis: An Unusual Endoscopic Finding", Clinical Gastroenterology and Hepatology, 12(5), pp.e37~e38 (2014), Elsevier BV[DOI]
296. Jean‐Michel Molina, "Albendazole for treatment and prophylaxis of microsporidiosis due to Encephalitozoon intestinalis in patients with AIDS: a randomized double-blind controlled trial", The Journal of Infectious Diseases, 177(5), pp.1373~1377 (1998), Oxford University Press (OUP)[DOI]
297. Leder K, "Microsporidial disease in HIV-infected patients : a report of 42 patients and review of the literature", Scand J Infect Dis 1998;, 30, pp.331~338 (1998)[DOI]
298. Tremoulet AH, "Albendazole therapy for Microsporidium diarrhea in immunocompetent Coasta Rican children", Ped Infect Dis J, 23, pp.915~918 (2004)[DOI]
299. Molina JM, "Intestinal microsporidiosis in human immunodeficiency virusinfected patients with chronic unexplained diarrhea: prevalence and clinical and biological features", J Infect Dis, 167, pp.217~221 (1993)[DOI]
300. Dieterich DT, "Treatment with albendazole for intestinal disease due to Enterocytozoon bieneusi in patients with AIDS", J Infect Dis, 169, pp.178~183 (1994)[DOI]
301. Wichro E, "Microsporidiosis in travel-associated chronic diarrhea in immune-competent patients", Am J Trop Med Hyg, 73, pp.285~287 (2005)[DOI]
302. A. L. Galvan, "First Cases of Microsporidiosis in Transplant Recipients in Spain and Review of the Literature", Journal of Clinical Microbiology, 49(4), pp.1301~1306 (2011), American Society for Microbiology[DOI]
303. Molina JM, "Trial of oral fumagillin for the treatment of intestinal microsporidiosis in patients with HIV infection", AIDS, 14, pp.1341~1348 (2000)
304. F. Lanternier, "Microsporidiosis in solid organ transplant recipient: two Enterocytozoon bieneusi cases and review", Transplant Infectious Disease, 11(1), pp.83~88 (2009), Wiley[DOI]
305. George B, "Disseminated microsporidiosis with Encephalitozoon species in a renal transplant recipient", Nephrology, 17(suppl), pp.5~8 (2012)[DOI]
306. Boileau M, "Successful treatment of disseminated Anncalia algerae microsporidial infection with combination fumagillin and albendazole", Open Forum Infect Dis, 3, pp.1~4 (2016)[DOI]
307. S K Katiyar, "In vitro susceptibilities of the AIDS-associated microsporidian Encephalitozoon intestinalis to albendazole, its sulfoxide metabolite, and 12 additional benzimidazole derivatives", Antimicrobial Agents and Chemotherapy, 41(12), pp.2729~2732 (1997), American Society for Microbiology[DOI]
308. D.L. Morris, "Albendazole in hydatid disease—hepatocellular toxicity", Transactions of the Royal Society of Tropical Medicine and Hygiene, 81(2), pp.343~344 (1987), Oxford University Press (OUP)[DOI]
309. Todorov T, "Albendazole treatment of human cystic echinococcosis", Trans R Soc Trop Med Hyg, 81, pp.343~344 (1987)[DOI]
310. Bülent O Yildiz, "Albendazole-Induced Amegakaryocytic Thrombocytopenic Purpura", Annals of Pharmacotherapy, 32(7-8), pp.842~842 (1998), SAGE Publications[DOI]
311. Polat C, "Dual treatment of albendazole in hepatic hydatidosis: new therapeutic modality in 52 cases", J Gastroenterol Hepatol, 20, pp.421~425 (2005)[DOI]
312. Nadia Ben Fredj, "Albendazole-induced associated acute hepatitis and bicytopenia", Scandinavian Journal of Infectious Diseases, 46(2), pp.149~151 (2013), Informa UK Limited[DOI]
313. Mohammad H. Pourgholami, "Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer", Cancer Chemotherapy and Pharmacology, 65(3), pp.597~605 (2010), Springer Science and Business Media LLC[DOI]
314. 김민관, "알벤다졸(400 mg) 1회 복용에 의해 유발된 급성 독성간염 1예", 대한내과학회지, 75(5), pp.564~568 (2008), 대한내과학회
315. 최기영, "Acute Drug-Induced Hepatitis Caused by Albendazole", Journal of Korean Medical Science, 23(5), pp.903~905 (2008), 대한의학회
316. Juan Ignacio Marin Zuluaga, "Albendazole-induced granulomatous hepatitis: a case report", Journal of Medical Case Reports, 7(1), pp.201~ (2013), Springer Science and Business Media LLC[DOI]
317. Bilgic Y, "Albendazole induced recurrent acute toxic hepatitis: a case report", Acta Gastro-enterol Belg, 80, pp.309~311 (2017)
318. Janaina Luz Narciso-Schiavon, "Recurrent albendazole-induced acute hepatitis", Revista Colombiana de Gastroenterología, 33(4), pp.473~ (2018), Asociacion Colombiana de Gastroenterologia[DOI]
319. Amoruso C, "Acute hepatitis as a side effect of albendazole: a pediatric case", Pediatr Med Chir, 31, pp.176~178 (2009)
320. Nandi M, "Albendazole-induced recurrent hepatitis", Indian Pediatr, 50, pp.1064~ (2013)
321. Chirag Shah, "Recurrent acute hepatitis caused by albendazole", Tropical Gastrology, 34(1), pp.38~39 (2013), EMED Publishing[DOI]
322. Alina Grama, "Etiology and Outcome of Acute Liver Failure in Children—The Experience of a Single Tertiary Care Hospital from Romania", Children, 7(12), pp.282~ (2020), MDPI AG[DOI]
323. C. M. Batzlaff, "Acute renal failure associated with albendazole therapy in a patient with trichinosis", Case Reports, 2014(may19 1), pp.bcr2013200668~bcr2013200668 (2014), BMJ[DOI]
324. Manlio Tolomeo, "Hepatotoxicity caused by mebendazole in a patient with Gilbert's syndrome", Journal of Clinical Pharmacy and Therapeutics, 44(6), pp.985~987 (2019), Wiley[DOI]
325. Seitz R, "Hepatocellular drug reaction caused by mebendazole therapy in cystic echinococcosis", Z Gastroenterol, 21, pp.324~323 (1983)
326. Bekhti A, "Hepatotoxicity of mebendazole. Relationship with serum concentrations of the drug", Gastroenterol Clin Biol, 11, pp.701~703 (1987)
327. Miskovitz PF, "Leukopenia associated with mebendazole therapy of hydatid disease", Am J Trop Med Hyg, 29, pp.1356~1358 (1980)[DOI]
328. Chen KT, "utbreak of Stevens-Johnson syndrome", toxic epidermal necrolysis associated with mebendazole and metronidazole use among Filipino laborers in Taiwan, 2003, pp.93, 489~492
329. Marcel S.G. Kwa, "Benzimidazole resistance in Haemonchus contortus is correlated with a conserved mutation at amino acid 200 in β-tubulin isotype 1", Molecular and Biochemical Parasitology, 63(2), pp.299~303 (1994), Elsevier BV
330. Pierre Dorny, "Failure of Mebendazole in Treatment of Human Hookworm Infections in the Southern Region of Mali", The American Journal of Tropical Medicine and Hygiene, 57(1), pp.25~30 (1997), American Society of Tropical Medicine and Hygiene[DOI]
331. Furtado LVF, "First identification of the F200Y SNP in the β-tubulin gene linked to benzimidazole resistance in Ancylostoma caninum", Vet Parasitol, 206, pp.313~316 (2014)[DOI]
332. Lauren Hubert Jaeger, "Status of benzimidazole resistance in intestinal nematode populations of livestock in Brazil: a systematic review", BMC Veterinary Research, 13(1), pp.358~ (2017), Springer Science and Business Media LLC[DOI]
333. Luis Fernando Viana Furtado, "Albendazole resistance induced in Ancylostoma ceylanicum is not due to single-nucleotide polymorphisms (SNPs) at codons 167, 198, or 200 of the beta-tubulin gene, indicating another resistance mechanism", Parasitology Research, 118(3), pp.837~849 (2019), Springer Science and Business Media LLC[DOI]
334. S. Geerts, "Anthelmintic resistance in human helminths: a review", Tropical Medicine and International Health, 6(11), pp.915~921 (2001), Wiley[DOI]
335. Marco Albonico, "Molecular analysis of the β-tubulin gene of human hookworms as a basis for possible benzimidazole resistance on Pemba Island", Molecular and Biochemical Parasitology, 134(2), pp.281~284 (2004), Elsevier BV[DOI]
336. A Bennett, "Reducing Intestinal Nematode Infection: Efficacy of Albendazole and Mebendazole", Parasitology Today, 16(2), pp.71~77 (2000), Elsevier BV[DOI]
337. Albonico M, "Efficacy of mebendazole and levamisole alone or in combination against intestinal nematode infections after repeated targeted mebendazole treatment in Zanzibar", Bull World Health Organ, 8, pp.343~352 (2003)
338. JIM CAMPBELL, "LOW EFFICACY OF MEBENDAZOLE AGAINST HOOKWORM IN VIETNAM: TWO RANDOMIZED CONTROLLED TRIALS", The American Journal of Tropical Medicine and Hygiene, 76(4), pp.732~736 (2007), American Society of Tropical Medicine and Hygiene[DOI]
339. Welbeck Amoani Twum, "Epidemiology of Hookworm Infection in Kintampo North Municipality, Ghana: Patterns of Malaria Coinfection, Anemia, and Albendazole Treatment Failure", The American Journal of Tropical Medicine and Hygiene, 84(5), pp.792~800 (2011), American Society of Tropical Medicine and Hygiene[DOI]
340. Aissatou Diawara, "Assays to Detect β-Tubulin Codon 200 Polymorphism in Trichuris trichiura and Ascaris lumbricoides", PLoS Neglected Tropical Diseases, 3(3), pp.e397~ (2009), Public Library of Science (PLoS)[DOI]
341. Aïssatou Diawara, "Association between Response to Albendazole Treatment and β-Tubulin Genotype Frequencies in Soil-transmitted Helminths", PLoS Neglected Tropical Diseases, 7(5), pp.e2247~ (2013), Public Library of Science (PLoS)[DOI]
342. Jozef Vercruysse, "Assessment of the Anthelmintic Efficacy of Albendazole in School Children in Seven Countries Where Soil-Transmitted Helminths Are Endemic", PLoS Neglected Tropical Diseases, 5(3), pp.e948~ (2011), Public Library of Science (PLoS)[DOI]
343. ROGER K. PRICHARD, "DETECTION OF BENZIMIDAZOLE RESISTANCE–ASSOCIATED MUTATIONS IN THE FILARIAL NEMATODE WUCHERERIA BANCROFTI AND EVIDENCE FOR SELECTION BY ALBENDAZOLE AND IVERMECTIN COMBINATION TREATMENT", The American Journal of Tropical Medicine and Hygiene, 73(2), pp.234~238 (2005), American Society of Tropical Medicine and Hygiene[DOI]
344. JACQUELINE UPCROFT, "Albendazole resistance in Giardia is correlated with cytoskeletal changes but not with a mutation at amino acid 200 in β-tubulin", Microbial Drug Resistance, 2(3), pp.303~308 (1996), Mary Ann Liebert Inc[DOI]
345. Ernest Lacey, "Activity of benzimidazole carbamates against L1210 mouse leukaemia cells: Correlation with in vitro tubulin polymerization assay", Biochemical Pharmacology, 34(19), pp.3603~3605 (1985), Elsevier BV[DOI]
346. Rolin S, "Study of the in vitro bioactivation of albendazole in human liver microsomes and hepatic cell lines", Cell Biol Toxicol 1989;, 5, pp.1~14 (1989)[DOI]
347. Mohammad Hossein Pourgholami, "Albendazole: a Potent Inhibitor of Vascular Endothelial Growth Factor and Malignant Ascites Formation in OVCAR-3 Tumor-Bearing Nude Mice", Clinical Cancer Research, 12(6), pp.1928~1935 (2006), American Association for Cancer Research (AACR)[DOI]
348. Ehteda A, "Combination of albendazole and 2-methoxyestradiol significantly improves the survival of HCT-116 tumor-bearing nude mice", BMC Cancers, 13, pp.86~ (2013)[DOI]
349. Sepideh Javdan, "Cytotoxic Effect of Albendazole on the Breast Cancer and Melanoma Cell Lines", Zahedan Journal of Research in Medical Sciences, 20(6), pp.e9100~ (2018), Briefland[DOI]
350. Priotti J, "Repositioning of anti-parasitic drugs in cyclodextrin inclusion complexes for treatment of triple-negative breast cancer", AAPS PharmEciTech, 19, pp.3734~3741 (2018)[DOI]
351. Kirtesh Patel, "Albendazole sensitizes cancer cells to ionizing radiation", Radiation Oncology, 6(1), pp.160~ (2011), Springer Science and Business Media LLC[DOI]
352. Cho YK, "Antiangiogenesis effect of albendazole on the cornea", J Ocul Pharmacol Ther, 35, pp.1~8 (2019)[DOI]
353. Xuan Zhang, "Anthelmintic drug albendazole arrests human gastric cancer cells at the mitotic phase and induces apoptosis", Experimental and Therapeutic Medicine, 13(2), pp.595~603 (2017), Spandidos Publications
354. Yang MH, "Albendazole exhibits anti-neoplastic actions against gastric cancer cells by affecting STAT3 and SATAT5 activation by pleiotropic mechanism(s)", Biomedicines, 9, pp.362~ (2021)[DOI]
355. Farhad Ghasemi, "Repurposing Albendazole: new potential as a chemotherapeutic agent with preferential activity against HPV-negative head and neck squamous cell cancer", Oncotarget, 8(42), pp.71512~71519 (2017), Impact Journals, LLC[DOI]
356. Zhang QL, "Antitumor effect of albendazole on cutaneous squamous cell carcinoma (SCC) cells", BioMed Res Int, 2019, pp.3689517~ (2019)[DOI]
357. Dogra N, "Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways", Sci Rep, 8, pp.11926~ (2018)[DOI]
358. Movahedi F, "Nanoformulations of albendazole as effective anticancer and antiparasite agents", Nanomedicine, 12, pp.2555~2574 (2017)[DOI]
359. Roxana Racoviceanu, "Solid Polymeric Nanoparticles of Albendazole: Synthesis, Physico-Chemical Characterization and Biological Activity", Molecules, 25(21), pp.5130~ (2020), MDPI AG[DOI]
360. Mukhopadhyay T, "Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo", Clin Cancer Res, 8, pp.2963~2969 (2002)
361. Sasaki J, "The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells", Mol Cancer Therapeut, 1, pp.1201~1209 (2002)
362. Martarelli D, "Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice", Cancer Chemother Pharmacol, 61, pp.809~817 (2008)[DOI]
363. Nicole Doudican, "Mebendazole Induces Apoptosis via Bcl-2 Inactivation in Chemoresistant Melanoma Cells", Molecular Cancer Research, 6(8), pp.1308~1315 (2008), American Association for Cancer Research (AACR)[DOI]
364. Bai RY, "Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme", Neuro-Oncology, 13, pp.974~982 (2011)[DOI]
365. Nygren P, "Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer", J cancer Res Clin Oncol, 139, pp.2133~2140 (2013)[DOI]
366. De Witt M, "Repurposing mebendazole as a replacement for vincristine for the treatment of brain tumors", Mol Med, 23, pp.50~56 (2017)[DOI]
367. Lai SR, "In vitro anti-tubulin effects of mebendazole and fenbendazole in canine glioma cells", Vet Comp Oncol, 15, pp.1445~1454 (2017)[DOI]
368. Suganthapriya Elayapillai, "Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer", Gynecologic Oncology, 160(1), pp.302~311 (2021), Elsevier BV[DOI]
369. Linda K. Rushworth, "Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment", British Journal of Cancer, 122(4), pp.517~527 (2020), Springer Science and Business Media LLC[DOI]
370. Irina Y. Dobrosotskaya, "Mebendazole Monotherapy and Long-Term Disease Control in Metastatic Adrenocortical Carcinoma", Endocrine Practice, 17(3), pp.e59~e62 (2011), Elsevier BV[DOI]
371. Nygren P, "Drug repositioning from bench to bedside : tumor remission by the antihelmintic drug mebendazole in refractory metastatic colon cancer", Acta Oncol, 53, pp.427~428 (2014)[DOI]

관련 논문AI추천